Reata Pharmaceuticals (RETA) PT Raised to $210 at Stifel After KOL Sees 80% Probability of First Pass Approval
Tweet Send to a Friend
Stifel analyst Adam Walsh raised the price target on Reata Pharmaceuticals (NASDAQ: RETA) to $210.00 (from $135.00) after KOL feedback ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
